Our enhancement platform will improve gene therapies by inducing a state of tolerance and dampening adverse pro-inflammatory reactions. We will accomplish immune tolerance by inducing tolerance in antigen presenting cells, activating Treg cells, and up-regulating cytokines that are immunosupressive. Furthermore, our novel therapeutic sends "anti-danger" signals to the host immune system to prevent adverse immune reactions that are often responsible for loss of efficacy.
We are leveraging our platform technology to develop a robust portfolio of next-generation biologics. Our platform will enable multiple doses while also enhancing efficacy of the first dose.